The statistics regarding drug use among the American workforce are alarming. An estimated one in 12 U.S. workers has a substance use disorder (SUD), and more than half of all adults diagnosed with an SUD are employed full-time. Many more members of t…
An exclusive life sciences webinar hosted recently by Sedgwick’s brand protection experts offered insight into the latest product safety challenges facing medical device, pharmaceutical and life sciences companies, including an insightful discussion …
The product recall by Denver-based marijuana cultivator Bonsai Cultivation reminds us of the unique regulatory dynamic facing the cannabis industry. In this case, the cultivator – working with state officials – pulled marijuana products off the marke…
When there’s a recall, consumers think of the name on the package. Often that brand is the single company believed to be responsible, and that company is the one whose reputation is diminished. Perhaps nowhere is this more apparent than the food indu…
We’ve seen sweeping regulatory changes before, but the FDA’s anticipated regulation of cannabis and CBD-infused products – a market expected to reach more than $20B globally by 2024 – promises to pose significant and unprecedented challenges to food …
On September 27, 2018, the Drug Enforcement Agency (DEA) made a remarkable move. The agency placed a cannabidiol (CBD) containing product, Epidiolex, into Schedule V (classified as having low potential for abuse) so that it could be manufactured in t…